drugset
Drugs / Alpha-1 Antitrypsin (human)
last change Aug 2019 re-read 3 minutes ago

Alpha-1 Antitrypsin (human)

also known as AAT · alpha-1 antitrypsin

Protein / enzyme biologic

Developed for
alpha 1-antitrypsin deficiency
Investigated by
CSL Behring · Michael Campos, MD

Trials 1

today NCT01669421 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01669421 Jul 2012 → May 2016 alpha 1-antitrypsin deficiency Michael Campos, MD Completed Mixed

Press releases naming this drug 4 releases

DateIssuerRelease
2016-12-02 CSL Behring The Lancet Respiratory Medicine Publishes RAPID Extension Study Data Confirming Disease-modifying Effect of Respreeza® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD) csl.com ↗
2015-09-28 CSL Behring New Clinical Data on Treatment to Slow the Progression of Emphysema in Patients with Alpha-1 Antitrypsin Deficiency Presented at European Respiratory Society International Congress in Amsterdam csl.com ↗
2015-06-29 CSL Behring CSL Behring Receives Positive CHMP Opinion for Respreeza® as Maintenance Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients in Europe csl.com ↗
2015-06-01 CSL Behring The Lancet Publishes CSL Behring’s Alpha-1 Antitrypsin Deficiency Study Data csl.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Alpha-1 Antitrypsin (human) ClinicalTrials.gov intervention name — accepted as the source's own label NCT01669421 ↗
Known as AAT “Augmentation therapy with intravenous AAT (alpha-1 antitrypsin) is the only specific therapy for individuals with pulmonary disease from AAT deficiency (AATD).” PMID 30965011 ↗ Aug 2019
Known as alpha-1 antitrypsin “Augmentation therapy with intravenous AAT (alpha-1 antitrypsin) is the only specific therapy for individuals with pulmonary disease from AAT deficiency (AATD).” PMID 30965011 ↗ Aug 2019
Action Inhibit “AAT has shown not only to inhibit lung proteases such as neutrophil elastase, but also to modulate inflammation.” NCT01669421 ↗
Modality Protein / enzyme biologic “administration of intravenous purified alpha-1 antitrypsin (augmentation therapy)” NCT01669421 ↗
Route Intravenous “administration of intravenous purified alpha-1 antitrypsin (augmentation therapy)” NCT01669421 ↗